PPARγ agonists or activators can promote macrophage cholesterol efflux and protect against atherosclerosis by augmenting the expression of LXRα and ABCA1/G1 (Chawla et al., 2001; Ren et al., 2019; Du et al., 2021). This evidence concerns the gene ABCA1 and atherosclerosis.